The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education, research, advocacy, and collaboration, has appointed Brian G. DeRubertis, MD, and Kathleen Gibson, MD, as the newest members of the Board of Directors.
Drs. DeRubertis and Gibson have been valued partners of The VIVA Foundation for several years, serving as conference faculty, program committee members, and in advocacy roles during the Vascular Leaders Forum. Their expertise and experience to support will support The Foundation's mission.
Dr. DeRubertis is the Chief of the Division of Vascular & Endovascular Surgery at New York Presbyterian Hospital-Weill Cornell Medical School in New York City and is a Fellow of the American College of Surgeons. After obtaining his undergraduate degree at the University of California, Los Angeles, Dr. DeRubertis earned his medical degree, residency, and fellowship training at Weill Cornell Medical College and Columbia University training programs. He earned the rank of Professor of Surgery at the UCLA School of Medicine where he spent nearly 15 years with the Division of Vascular Surgery before returning to New York to rejoin Cornell’s Department of Surgery.
Dr. DeRubertis has participated in more than 25 clinical research studies, including roles as National Principal Investigator in the LIFE-BTK, Magical BTK and VIVA REALITY trials.
Dr. Kathleen Gibson is a board-certified vascular surgeon and partner at Lake Washington Vascular Surgeons in Bellevue, Washington. She graduated with highest honors from the University of Washington School of Medicine in Seattle. Her fellowship, residency and undergraduate degree in Chemical Engineering were all completed at the University of Washington. She serves on the Executive Board of the American Vein and Lymphatic Society and is its current President. She is a distinguished member of the American Venous Forum and is a member of the Society for Vascular Surgery.
Dr. Gibson has authored or co-authored multiple book chapters and articles and has been an investigator for more than 42 clinical trials.
Please join us in congratulating these leaders in vascular care.